Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

The CATNON trial investigated the addition of concurrent, adjuvant, and both current and adjuvant temozolomide to radiotherapy in adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas. The benefit of concurrent temozolomide chemotherapy and relevance of mutations in the IDH1 and IDH2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology 2021-06, Vol.22 (6), p.813-823
Hauptverfasser: van den Bent, Martin J, Tesileanu, C Mircea S, Wick, Wolfgang, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Erridge, Sarah, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean Français, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Caparrotti, Francesca, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Lim, Elizabeth, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, de Heer, Iris, Aldape, Kenneth, Jenkins, Robert B, Dubbink, Hendrikus Jan, Kros, Johan M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, French, Pim, Baumert, Brigitta G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!